Literature DB >> 33478264

The safety of current pharmacotherapeutic strategies for osteosarcoma.

Mariella Spalato1, Antoine Italiano1,2.   

Abstract

Introduction: Peri-operative chemotherapy is the backbone of treatment for patients with osteosarcoma. Methotrexate, cisplatinum, doxorubicin and ifosfamide are the main drugs used in chemotherapy regimens used for osteosarcoma.Areas covered: We have reviewed here the relevant literature related to the incidence and management of acute and late toxicities of systemic treatment used for the management of patients with osteosarcoma.Expert opinion: Early diagnosis and appropriate management of acute and late toxicities of chemotherapy is crucial for an efficient care of osteosarcoma patients. Although the incidence and management of chemotherapy-related acute toxicities are well known by most oncologists, the use of high doses of methotrexate have the potential to cause fatal toxicities and, therefore, needs careful monitoring. Moreover, the diagnosis of late toxicities is more challenging and requires long-term follow-up for an appropriate management.

Entities:  

Keywords:  Osteosarcoma; chemotherapy; cisplatinum; doxorubicin; ifosfamide; methotreaxta; safety

Year:  2021        PMID: 33478264     DOI: 10.1080/14740338.2021.1881060

Source DB:  PubMed          Journal:  Expert Opin Drug Saf        ISSN: 1474-0338            Impact factor:   4.250


  2 in total

1.  Epithelial to Mesenchymal Transition Relevant Subtypes with Distinct Prognosis and Responses to Chemo- or Immunotherapies in Osteosarcoma.

Authors:  Yang Zhou; Gai Li; Hu Li; Fuchong Lai; Pingguo Duan; Ming Cheng
Journal:  J Immunol Res       Date:  2022-07-04       Impact factor: 4.493

2.  Targeting Bone Tumor and Subcellular Endoplasmic Reticulum via Near Infrared II Fluorescent Polymer for Photodynamic-Immunotherapy to Break the Step-Reduction Delivery Dilemma.

Authors:  Xianghong Zhang; Jia Wan; Fuhao Mo; Dongsheng Tang; Haihua Xiao; Zhihong Li; Jinpeng Jia; Tang Liu
Journal:  Adv Sci (Weinh)       Date:  2022-06-26       Impact factor: 17.521

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.